January 16, 2018 / 1:11 PM / in 9 months

BRIEF-Redhill Biopharma Announces Final Results From Phase II Study With Bekinda For IBS-D

Jan 16 (Reuters) - Redhill Biopharma Ltd:

* REDHILL BIOPHARMA ANNOUNCES FINAL RESULTS FROM PHASE II STUDY WITH BEKINDA® FOR IBS-D

* REDHILL BIOPHARMA - INDEPENDENT REVIEW & ANALYSIS OF FINAL RESULTS CONFIRMED THAT PHASE II STUDY WITH BEKINDA 12 MG SUCCESSFULLY MET PRIMARY ENDPOINT

* REDHILL BIOPHARMA - PLANS TO MEET WITH FDA IN H1 2018 TO DISCUSS DESIGN FOR ONE OR TWO PIVOTAL PHASE III STUDIES WITH BEKINDA 12 MG FOR IBS-D Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below